For Gynecologic Cancer Awareness Month, Amy Schultz, RN, details symptom identification, barrier mitigation, and caregiver support in oncology care.
|Videos|January 30, 2016
Learn More About T.E.A.L.
Advertisement
Tell Every Amazing Lady's mission is to promote public awareness and education of the signs, symptoms and risk factors of Ovarian Cancer, while providing support to survivors and raising funds for research in order to find the cure for Ovarian Cancer.
Visit
Advertisement
Related to this article
In the phase 2 EVITA trial, vitamin C did not slow clonal growth but was linked to fewer serious adverse events and longer exploratory survival.
Marieta Branis, APN, discusses individualized breast cancer care, monitoring for ADC and oral therapy toxicities, younger patients, and survivorship.
In a randomized trial, 73% of relatives offered navigation completed genetic testing within 6 months vs 51% of those who received a family letter.
In observation of National PA Week, Moffitt PA Mark Honor details top-of-license nursing collaboration and outpatient end-stage hematology care.
Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.
Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Breast Cancer Awareness: An APN on Personalized Care and Survivorship
2
Oral Vitamin C Misses Primary End Point in CCUS but Shows Survival Signal
3
FDA Approves Atezolizumab Plus Chemo for Stage 3 dMMR Colon Cancer
4
National PA Week: PA-Nurse Synergy Transforms Outpatient Hematology Care
5